Neuroprotective effects of Psoralea corylifolia Linn seed extracts on mitochondrial dysfunction induced by 3-nitropropionic acid

BMC Complementary and Alternative Medicine

Mi-Young Lee¹  Gui jun Zhang²  Sung-Wook Chae¹  A-Rang Im¹ 

[1]KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon 305-811, Korea

[2]School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China

关键词: Cellular bioenergetics;    Mitochondrial dysfunction;    3-nitropropionic acid;    Psoralea corylifolia Linn seed;   

Others  :  1086419
DOI  :  10.1186/1472-6882-14-370

 received in 2014-05-07, accepted in 2014-09-29,  发布年份 2014

【 摘 要 】

Background

Mitochondrial dysfunction has been implicated in neuronal apoptosis associated with neurodegenerative diseases such as Huntington’s disease (HD). Animals that are administered 3-nitropropionic acid (3-NP), a mitochondrial toxin that specifically inhibits complex II of the mitochondrial electron transport chain, manifest HD-like symptoms.

Methods

Psoralea corylifolia Linn seed extracts against 3-NP induced mitochondrial dysfunction in cultured rat pheochromocytoma (PC12) cells, which are used for neurobiological studies.

Results

In this study showed that 3-NP-treated PC12 cells had decreased ATP levels, lower cellular oxygen consumption, and reduced mitochondrial membrane potential than those of untreated PC12 cells. Psoralea corylifolia Linn seed extracts stimulated mitochondrial respiration with uncoupling and induced an increased bioenergetic reserve capacity. Furthermore, PC12 cells pretreated with P. corylifolia Linn seed extracts significantly attenuated 3-NP-induced cell death, reduced ATP levels, and lowered the mitochondrial membrane potential.

Conclusions

These results demonstrate that P. corylifolia Linn seed extracts have a significant protective effect against 3-NP induced cytotoxicity. Thus, our results indicate that P. corylifolia Linn seed extracts may have potential applications as therapeutic agents for treating neurodegenerative disease.

【 授权许可】

   
2014 Im et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Khushboo PS, Jadhav VM, Kadam VJ, Sathe NS: Psoralea corylifolia Linn.-"Kushtanashini". Pharmacogn Rev 2010, 4(7):69-76.
• [2]Latha PG, Evans DA, Panikkar KR, Jayavardhanan KK: Immunomodulatory and antitumour properties of Psoralea corylifolia seeds. Fitoterapia 2000, 71(3):223-231.
• [3]Anand KK, Sharma ML, Singh B, Ghatak BJ: Antiinflammatory, antipyretic & analgesic properties of bavachinin-a flavanone isolated from seeds of Psoralea corylifolia Linn. (Babchi). Indian J Exp Biol 1978, 16(11):1216-1217.
• [4]Arora R, Dhaker AS, Adhikari M, Sharma J, Chawla R, Gupta D, Zheleva A, Karamalakova Y, Kumar R, Sharma A, Sultana S, Sharma RK, Tripathi RP, Gadjeva V: Radical scavenging and radiomodulatory effects of Psoralea corylifolia Linn. substantiated by in vitro assays and EPR spectroscopy. Zeitschrift fur Naturforschung C J Biosci 2011, 66(1–2):35-46.
• [5]Tsai MH, Huang GS, Hung YC, Bin L, Liao LT, Lin LW: Psoralea corylifolia extract ameliorates experimental osteoporosis in ovariectomized rats. Am J Chin Med 2011, 35(4):669-680.
• [6]Zhao G, Zheng XW, Qin GW, Gai Y, Jiang ZH, Guo LH: In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.). Cell Mol Life Sci 2009, 66(9):1617-1629.
• [7]Yi LT, Li YC, Pan Y, Li JM, Xu Q, Mo SF, Qiao CF, Jiang FX, Xu HX, Lu XB, Kong LD, Kung HF: Antidepressant-like effects of psoralidin isolated from the seeds of Psoralea Corylifolia in the forced swimming test in mice. Prog Neuro-Psychoph 2008, 32(2):510-519.
• [8]Chen Y, Kong LD, Xia X, Kung HF, Zhang L: Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the forced swimming test in mice. J Ethnopharmacol 2005, 96(3):451-459.
• [9]Chen Y, Wang HD, Xia X, Kung HF, Pan Y, Kong LD: Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the chronic mild stress model of depression in mice. Phytomedicine 2007, 14(7–8):523-529.
• [10]Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Rosen BR, Hyman BT: Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13(10):4181-4192.
• [11]Liot G, Bossy B, Lubitz S, Kushnareva Y, Sejbuk N, Bossy-Wetzel E: Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Dis 2009, 16(6):899-909.
• [12]Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S: Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011, 2011:683728.
• [13]Trushina E, McMurray CT: Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007, 145(4):1233-1248.
• [14]Ederico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E: Mitochondrial oxidative stress and neurodegeneration. J Neurol Sci 2012, 322(1–2):254-262.
• [15]Andreyev AY, Kushnareva YE, Starkov AA: Mitochondrial metabolism of reactive oxygen species. Biochemistry 2005, 70(2):200-214.
• [16]Swerdlow RH: Mitochondrial Medicine and the Neurodegenerative Mitochondriaopathies. Pharmaceuticals 2009, 2(3):150-167.
• [17]Choi SW, Gerencser AA, Nicholls DG: Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem 2009, 109(4):1179-1191.
• [18]Zhao G, Zheng XW, Qin GW, Gai Y, Jiang ZH, Guo LH: In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.). Cell Mol Life Sci 2009, 66(9):1617-1629.
• [19]Zhao G, Li S, Qin GW, Fei J, Guo LH: Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter. J Ethonopharmacol 2007, 112(3):498-506.
• [20]Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF: Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997, 41(5):646-653.
• [21]Brennan WA Jr, Bird ED, Aprille JR: Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985, 44(6):1948-1950.
• [22]Borlonqan CV, Koutouzis TK, Sanberq PR: 3-Nitropropionic acid animal model and Huntington’s disease. Neurosci Biobehav Rev 1997, 21(3):289-293.
• [23]Vis JC, Verbeek MM, De Waal RM, Ten Donkelaar HJ, Kremer HP: 3-Nitropropionic acid induces a spectrum of Huntington’s disease-like neuropathology in rat striatum. Neuropathol Appl Neurobiol 1999, 25(6):513-521.
• [24]Schulz JB, Matthews RT, Klochqether TJ, Dichqans MF: The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 1997, 174(1–2):193-197. 1997